[
  {
    "ts": "2025-11-25T08:11:23+00:00",
    "headline": "Should FDA Approval of PADCEV-Keytruda Combo Shape the Outlook for Pfizer (PFE) Investors?",
    "summary": "Pfizer and Astellas Pharma have received FDA approval for PADCEV, an antibody-drug conjugate, in combination with Keytruda as a neoadjuvant and adjuvant therapy for muscle-invasive bladder cancer in patients ineligible for cisplatin-containing chemotherapy, following strong results from the Phase 3 EV-303 trial. This milestone extends Pfizer’s reach in oncology by offering a much-needed treatment option for patients with limited chemotherapy alternatives and underscores ongoing progress in...",
    "url": "https://finance.yahoo.com/news/fda-approval-padcev-keytruda-combo-081123602.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "bc248386-7755-3e12-8e0c-a90745023b0b",
      "content": {
        "id": "bc248386-7755-3e12-8e0c-a90745023b0b",
        "contentType": "STORY",
        "title": "Should FDA Approval of PADCEV-Keytruda Combo Shape the Outlook for Pfizer (PFE) Investors?",
        "description": "",
        "summary": "Pfizer and Astellas Pharma have received FDA approval for PADCEV, an antibody-drug conjugate, in combination with Keytruda as a neoadjuvant and adjuvant therapy for muscle-invasive bladder cancer in patients ineligible for cisplatin-containing chemotherapy, following strong results from the Phase 3 EV-303 trial. This milestone extends Pfizer’s reach in oncology by offering a much-needed treatment option for patients with limited chemotherapy alternatives and underscores ongoing progress in...",
        "pubDate": "2025-11-25T08:11:23Z",
        "displayTime": "2025-11-25T08:11:23Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QSfydsi7Q.1zNEN99DbEyw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hi2p7oczHh8yTJraqZcczg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/fda-approval-padcev-keytruda-combo-081123602.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/fda-approval-padcev-keytruda-combo-081123602.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "4503.T"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]